Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection
- PMID:34757217
- DOI: 10.1016/j.bmcl.2021.128432
Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection
Abstract
Levonadifloxacin is a parenteral anti-MRSA benzoquinolizine antibacterial drug recently launched as, EMROK in India to treat acute bacterial skin and skin structure infections (ABSSSI) in hospitalized patients. As a step down therapy an oral form of levonadifloxacin with comparable PK/PD was needed because the levonadifloxacin exhibits very poor oral absorption. To improve the drugability in terms of oral absorption a pro-drug approach was evaluated. Structurally levonadifloxacin provides two sites amenable for ester or amide formation, a carboxyl function of benzoquinolizine pharmacophore and hydroxyl group on piperidine side chain. Several aliphatic, aromatic and amino acid esters of C-2 carboxylic acid, C-4-hydroxyl piperidine and double esters at both C-2, C-4 positions were synthesized. The cleavage of prodrugs was studied in vitro as well as in animal models to access their suitability as prodrug function. Among C-2 carboxylic ester prodrugs, daloxate (WCK 2320) showed highest cleavage in serum as well as in liver enzyme; however its stability in aqueous solution was unfavorable. In contrast, most of the esters at the hydroxyl group like propionyl ester (WCK 2305) and amino acid esters such as l-alanine (WCK 2349), l-valine (WCK 2630) were cleaved readily releasing active drug. Thus, indicating C-4-hydroxyl piperidine was amenable site for enzymatic cleavage over esters of C-2 carboxylic acid. Additionally, amino acid esters provided an opportunity to make salt, facilitating improved aqueous solubility. Methanesulfonate salt of l-alanine ester of levonadifloxacin (WCK 2349) was successfully developed and launched as oral prodrug alalevonadifloxacin (EMROK-O).
Keywords: Alalevonadifloxacin; EMROK-O; MRSA; Prodrug; WCK 2349.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
- Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M.Bhagwat SS, et al.Drug Des Devel Ther. 2019 Dec 24;13:4351-4365. doi: 10.2147/DDDT.S229882. eCollection 2019.Drug Des Devel Ther. 2019.PMID:31920285Free PMC article.Review.
- Assessment ofin vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes.Chavan R, Zope V, Chavan N, Shaikh J, Patil K, Yeole R, Bhagwat S, Patel M.Chavan R, et al.Xenobiotica. 2020 Oct;50(10):1149-1157. doi: 10.1080/00498254.2020.1756007. Epub 2020 Apr 22.Xenobiotica. 2020.PMID:32283993
- Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital.Bakthavatchalam YD, Shankar A, Muniyasamy R, Peter JV, Marcus Z, Triplicane Dwarakanathan H, Gunasekaran K, Iyadurai R, Veeraraghavan B.Bakthavatchalam YD, et al.J Antimicrob Chemother. 2020 Aug 1;75(8):2156-2159. doi: 10.1093/jac/dkaa142.J Antimicrob Chemother. 2020.PMID:32361727
- In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.Tellis M, Joseph J, Khande H, Bhagwat S, Patel M.Tellis M, et al.J Med Microbiol. 2019 Aug;68(8):1129-1136. doi: 10.1099/jmm.0.000999. Epub 2019 Jun 26.J Med Microbiol. 2019.PMID:31241446
- India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care.Veeraraghavan B, Bakthavatchalam YD, Manesh A, Lal B, Swaminathan S, Ansari A, Subbareddy K, Rangappa P, Choudhuri AH, Nagvekar V, Mehta Y, Appalaraju B, Baveja S, Baliga S, Shenoy S, Bhardwaj R, Kongre V, Dattatraya GS, Verma B, Mukherjee DN, Gupta S, Shanmugam P, Iravane J, Mishra SR, Barman P, Chopra S, Hariharan M, Surpam R, Pratap R, Turbadkar D, Taklikar S; Drug Discovery group, Wockhardt.Veeraraghavan B, et al.Indian J Med Microbiol. 2023 Jan-Feb;41:71-80. doi: 10.1016/j.ijmmb.2022.11.005. Epub 2022 Dec 9.Indian J Med Microbiol. 2023.PMID:36509611Review.
Cited by
- Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin.Mehta Y, Mishra KC, Paliwal Y, Rangappa P, Sinha S, Bhapkar S.Mehta Y, et al.Crit Care Res Pract. 2022 Sep 9;2022:2668199. doi: 10.1155/2022/2668199. eCollection 2022.Crit Care Res Pract. 2022.PMID:36785544Free PMC article.Review.
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.Shi Z, Zhang J, Tian L, Xin L, Liang C, Ren X, Li M.Shi Z, et al.Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.Molecules. 2023.PMID:36838752Free PMC article.Review.
- Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?Rusu A, Munteanu AC, Arbănași EM, Uivarosi V.Rusu A, et al.Pharmaceutics. 2023 Mar 1;15(3):804. doi: 10.3390/pharmaceutics15030804.Pharmaceutics. 2023.PMID:36986665Free PMC article.Review.
- Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.Lungu IA, Moldovan OL, Biriș V, Rusu A.Lungu IA, et al.Pharmaceutics. 2022 Aug 22;14(8):1749. doi: 10.3390/pharmaceutics14081749.Pharmaceutics. 2022.PMID:36015376Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous